Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics Ltd is positioned favorably for strategic partnerships due to converging regulatory and clinical milestones, particularly in North America and Europe. The company's PrimeC candidate has demonstrated a statistically significant 29.2% slowing of disease progression in its Phase 2b PARADIGM study, with even greater benefits noted for early treatment cohorts, highlighting its therapeutic potential. Additionally, the favorable safety and tolerability profile, along with biomarker-driven evidence of target engagement, reinforces the company's outlook as it prepares for late-stage activities and potential collaborations that could provide non-dilutive capital.

Bears say

NeuroSense Therapeutics Ltd is facing significant financial challenges as indicated by tightening cash reserves, which raises concerns about the company's liquidity and operational sustainability. The anticipated need for a capital raise suggests potential difficulties in funding ongoing clinical trials and development efforts for its product candidate, PrimeC, aimed at treating neurodegenerative diseases. As a result, these issues may hinder investor confidence and negatively impact the stock's performance in the market.

NRSN has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 1 analysts, NRSN has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.